Hydroxychloroquine News and Research

RSS

Hydroxychloroquine not associated with prolonged heart rhythm intervals in RA or lupus patients

New research presented at ACR Convergence, the American College of Rheumatology's annual meeting, discovers that use of hydroxychloroquine, a generic drug, does not cause any significant differences in QTc length or prolonged QTc, key measures of heart rate, in people with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).

6 Nov 2020

Reducing the airborne transmission risk for SARS-CoV-2

Rapid Reviews: COVID-19 (RR:C19), an open-access overlay journal published by the MIT Press that accelerates peer review of COVID-19-related research preprints, is currently soliciting reviews of the following COVID-19 preprints.

6 Nov 2020

Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines

A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv preprint server.

4 Nov 2020

Genome-wide CRISPR screens reveal resistance and sensitization mechanisms of drugs used in COVID-19

By leveraging nucleotide triphosphate analog-induced cell death, Chinese researchers unveiled genes that affect the import, export, and metabolism of pervasively used antiviral drugs in the treatment of coronavirus disease (COVID-19). This exciting study is currently available on the bioRxiv* preprint server.

28 Oct 2020

Research on autophagy and coronavirus, implicates ULK1

Researchers from the University of British Columbia have discovered that the betacoronavirus-encoded papain-like protease disrupts autophagy, partly by targeting ULK1. Their work is reported on the preprint server bioRxiv* in October 2020.

27 Oct 2020

Hydroxychloroquine does not prevent COVID-19 in health care workers, trial shows

University of Minnesota Medical School physician researchers studied hydroxychloroquine as a treatment to prevent COVID-19 for those with high-risk for exposure to the virus - health care workers.

21 Oct 2020

Scientists suggest that anti-malarial drugs could be repurposed to treat COVID-19

An international group of researchers believe there is enough evidence that anti-malarial drugs could be repurposed to treat COVID-19 and that they should be assessed for efficacy in clinical trials.

20 Oct 2020

Can ordinary COVID patients get the Trump treatment? It’s OK to ask

When Terry Mutter woke up with a headache and sore muscles on a recent Wednesday, the competitive weightlifter chalked it up to a hard workout.

20 Oct 2020

Template for COVID-19 management in a rural health system

As the COVID-19 pandemic continues to challenge existing health networks, a new study published on the preprint server medRxiv in October 2020 reports on a strategy to address existing health care disparities in rural and urban areas of the USA. This should draw attention to the need for more such systems to ensure proper rural healthcare in the current and future pandemics.

20 Oct 2020

WHO study finds Remdesivir and other repurposed drugs ineffective in COVID-19

A large-scale randomized trial has recently been conducted by the World Health Organization (WHO) to evaluate the efficacy of four repurposed antiviral medicines, including Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon, currently used to treat hospitalized coronavirus disease 2019 (COVID-19) patients.

18 Oct 2020

Control trial proves effectiveness of repurposed drugs for COVID-19 treatment

In just six months, the world's largest randomized control trial on COVID-19 therapeutics has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19.

16 Oct 2020

News coverage contributes to drug shortages in COVID-19

Researchers at Boston Children's Hospital in the U.S. have reported that the recent shortage of medicines used to treat coronavirus disease 2019 (COVID-19) could be due to extensive news media coverage that results in individual hoarding or institutional stockpiling of medicines.

15 Oct 2020

"Pandemic politics" is causing assaults on science and the public health

COVID-19 is now the third leading cause of death in the United States only behind cardiovascular disease and cancer.

14 Oct 2020

Genoscience Pharma's GNS561 shows potential against SARS-CoV-2 in vitro

A new study published on the preprint server bioRxiv in October 2020 shows that a combination of a new compound GNS561 and remdesivir act synergistically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This suggests that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.

12 Oct 2020

Pathways contributing to hypercoagulability in severe SARS‐CoV‐2 patients

In a study by researchers explored the possible mechanisms of the clotting disorder, focusing on the role of hypoxia-related activation of coagulation factors; cytokine storm, activation of neutrophils, and the release of neutrophil extracellular traps.

11 Oct 2020

Study compares the effect of hydroxychloroquine versus favipiravir in SARS-CoV-2−infected hamsters

Virologists at the Rega Institute have shown that the anti-malaria drug hydroxychloroquine does not limit SARS-CoV-2 coronavirus replication in hamsters.

9 Oct 2020

Severe COVID-19 during pregnancy associated with adverse maternal and neonatal outcomes

Pregnant women with severe or critical COVID-19 and their unborn infants face increased health risks before and after delivery, a Rutgers study finds.

8 Oct 2020

SARS-CoV-2 and anti-COVID-19 drugs activate Kaposi sarcoma-associated herpesvirus

A new study published on the preprint server bioRxiv* aimed to investigate the impacts of COVID-19 on people with various illnesses. Specifically, the researchers at the Rockefeller Cancer Institute, and the University of Arkansas for Medical Sciences wanted to see the effects of COVID-19 on patients with cancer and other infectious diseases.

6 Oct 2020

Human recombinant soluble ACE2 successfully used in a patient with severe COVID-19

A multinational research group recently published a paper in the journal Lancet Respiratory Medicine which describes the first patient with a severe form of coronavirus disease (COVID-19) that was successfully treated with human recombinant soluble ACE2.

27 Sep 2020

Brazil becomes global hotspot for COVID-19 pandemic

Two nationwide COVID-19 antibody seroprevalence studies from Brazil show that many cities along the Amazon were hit hardest at the beginning of the epidemic in May and June, along with poorer and Indigenous communities.

24 Sep 2020

Hydroxychloroquine News and Research

Hydroxychloroquine not associated with prolonged heart rhythm intervals in RA or lupus patients

Reducing the airborne transmission risk for SARS-CoV-2

Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines

Genome-wide CRISPR screens reveal resistance and sensitization mechanisms of drugs used in COVID-19

Research on autophagy and coronavirus, implicates ULK1

Hydroxychloroquine does not prevent COVID-19 in health care workers, trial shows

Scientists suggest that anti-malarial drugs could be repurposed to treat COVID-19

Can ordinary COVID patients get the Trump treatment? It’s OK to ask

Template for COVID-19 management in a rural health system

WHO study finds Remdesivir and other repurposed drugs ineffective in COVID-19

Control trial proves effectiveness of repurposed drugs for COVID-19 treatment

News coverage contributes to drug shortages in COVID-19

"Pandemic politics" is causing assaults on science and the public health

Genoscience Pharma's GNS561 shows potential against SARS-CoV-2 in vitro

Pathways contributing to hypercoagulability in severe SARS‐CoV‐2 patients

Study compares the effect of hydroxychloroquine versus favipiravir in SARS-CoV-2−infected hamsters

Severe COVID-19 during pregnancy associated with adverse maternal and neonatal outcomes

SARS-CoV-2 and anti-COVID-19 drugs activate Kaposi sarcoma-associated herpesvirus

Human recombinant soluble ACE2 successfully used in a patient with severe COVID-19

Brazil becomes global hotspot for COVID-19 pandemic

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News